Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

HemaSphere·2026
Same author

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.

Blood cancer journal·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Blood cancer journal·2026
Same author

Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection.

Clinical lymphoma, myeloma & leukemia·2026

Related Experiment Video

Updated: Mar 15, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K

Recent advances in understanding multiple myeloma.

Binod Dhakal1, Saulius Girnius2, Parameswaran Hari1

  • 1Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

F1000Research
|September 10, 2016
PubMed
Summary

Recent advancements in multiple myeloma management include revised diagnostic criteria and novel therapies. Understanding disease progression aids in selecting treatments, moving closer to a cure or long-term remission.

Keywords:
Multiple Myelomadiagnosismonoclonal antibodiestreatment

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma diagnosis and management have seen significant recent progress.
  • Understanding clonal evolution aids in disease management and therapeutic selection.
  • Revised diagnostic criteria now classify ultra-high-risk smoldering multiple myeloma as requiring treatment.

Purpose of the Study:

  • To review recent advancements in multiple myeloma understanding and treatment.
  • To highlight the impact of novel therapies and evolving treatment paradigms.
  • To discuss the potential for achieving a cure or long-term indolent disease course.

Main Methods:

  • Review of recent clinical studies and FDA drug approvals.
  • Analysis of advancements in understanding multiple myeloma biology and clonal architecture.
  • Evaluation of novel therapeutic approaches, including immune-based strategies.

Main Results:

  • Modern triplet induction therapies with proteasome inhibitors and immunomodulators are now standard.
  • Four new drugs approved in 2015 expanded treatment options for relapsed/refractory multiple myeloma.
  • High-dose therapy with autologous transplant improves outcomes in eligible patients.

Conclusions:

  • Multiple myeloma, while not yet curable, is increasingly manageable with multi-targeted approaches.
  • Evolving paradigms include promising immune therapies like adoptive cellular therapies and antibody manipulations.
  • Improved understanding of disease biology and relapse architecture brings us closer to lasting remission or cure.